Related Experiment Video
Updated: Jan 29, 2026

Exon Skipping in Directly Reprogrammed Myotubes Obtained from Human Urine-Derived Cells
Published on: May 7, 2020
Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping
Guanggui Ding1, Jian Wang1, Peikun Ding1
1a Department of Thoracic Surgery , Shenzhen People's Hospital, Second Clinical Medical College of Jinan University.
Abstract:
Patients with non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping can benefit from crizotinib treatment. Currently, the main resistance mechanisms to crizotinib are MET D1228N and Y1230C mutations. We reported a case of a Chinese NSCLC patient with MET exon 14 skipping detected by targeted next-generation sequencing (NGS) achieved clinical and imaging remission after crizotinib treatment. Then, amplification of multiple genes such as erb-b2 receptor tyrosine kinase 2 (HER2) was detected when disease progressed, indicating novel resistance mechanisms to crizotinib. Ultimately the patient died from cancer-related factors. This was the first NSCLC case with MET exon 14 skipping which reported the HER2 gene amplification at the time of progression during crizotinib treatment, indicating that bypass mechanisms contribute to the development of acquired resistance to MET inhibitors.
Insights
Crizotinib effectively treats non-small cell lung cancer (NSCLC) with MET exon 14 skipping. However, HER2 amplification emerged as a novel resistance mechanism, highlighting bypass pathways in acquired resistance to MET inhibitors.
Area of Science:
- Oncology
- Genetics
- Molecular Biology
Background:
- Non-small cell lung cancer (NSCLC) patients with MET exon 14 skipping mutations often respond to crizotinib.
- Established resistance mechanisms include MET D1228N and Y1230C mutations.
Observation:
- A Chinese NSCLC patient with MET exon 14 skipping achieved remission with crizotinib.
- Disease progression occurred, revealing amplification of multiple genes, including erb-b2 receptor tyrosine kinase 2 (HER2).
Findings:
- This case represents the first report of HER2 gene amplification in an NSCLC patient with MET exon 14 skipping during crizotinib treatment.
- The findings suggest that bypass mechanisms, such as HER2 amplification, contribute to acquired resistance against MET inhibitors.
Implications:
- Understanding novel resistance mechanisms like HER2 amplification is crucial for developing effective treatment strategies for NSCLC.
- This highlights the need for continuous monitoring and adaptive therapies in patients treated with MET inhibitors.
More Related Videos
Related Concept Videos
Exon Recombination
Exon shuffling follows “splice frame rules.” Each exon...
Data Reporting and Recording
Resistivity
Resistance
Types of Reports I: Hands-off Report
Following are the key components and categories of hand-off reports:
Purpose and Process:
RACE - Rapid Amplification of cDNA Ends

